Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia / Saglio, G; Kim, Dw; Issaragrisil, S; le Coutre, P; Etienne, G; Lobo, C; Pasquini, R; Clark, Re; Hochhaus, A; Hughes, Tp; Gallagher, N; Hoenekopp, A; Dong, M; Haque, A; Larson, Ra; Kantarjian, Hm; Moiraghi, B; Perez, M; Greil, R; Valent, P; Bosly, A; Martiat, P; Noens, L; André, M; Verhoef, G; Conchon, M; Souza, C; Nonino, A; Hungria, V; Zanichelli, Ma; Colturato, V; Forrest, D; Lipton, Jh; Savoie, Ml; Delage, R; Lalancette, M; Quintero, G; Gomez, M; Klamova, H; Faber, E; Bjerrum, Ow; Fredriksen, H; Vestergaard, H; Marcher, C; Kamel, H; Elzawam, H; Porkka, K; Remes, K; Reiffers, J; Guilhot, F; Facon, T; Tulliez, M; Guerci Bresler, Ap; Nicolini, Fe; Charbonnier, A; Rea, D; Johnson Ansah, A; Legros, L; Harousseau, Jl; Rigal Huguet, F; Escoffre, M; Gardembas, M; Guyotat, D; Cahn, Jy; Gattermann, N; Ottmann, O; Niederwieser, D; Stegelmann, F; Schafhausen, P; Brümmendorf, T; Duyster, J; Blumenstengel, K; Scheid, C; Kneba, M; Kwong, Yl; Masszi, T; Petrini, M; Alimena, G; Di Raimondo, F; Rosti, G; Rotoli, B; Pane, Fabrizio; Pungolino, E; Amadori, S; Abruzzese, E; Fioritoni, G; Lauria, F; Bosi, A; Martelli, M; Rambaldi, A; Ferrara, F; Nobile, F; Gobbi, M; Carella, Am; Orlandi, Em; Leoni, P; Tiribelli, M; Levis, A; Imamura, M; Takahashi, N; Tsukamoto, N; Chiba, S; Nagai, T; Okamoto, S; Miura, O; Kurokawa, M; Ohnishi, K; Toba, K; Nakao, S; Tomita, A; Miyamura, K; Hino, M; Maeda, Y; Kimura, A; Kawaguchi, T; Miyazaki, Y; Nakaseko, C; Jinnai, I; Matsuda, A; Matsumura, I; Ishikawa, J; Ohyashiki, K; Okada, M; Usuki, K; Kobayashi, Y; Ohishi, K; Imai, K; Miyawaki, S; Kanda, Y; Park, Sy; Kim, Hj; Sohn, Sk; Lee, Kh; Jung, Cw; Ong, Tc; Gómez Almaguer, D; Kassack, J; Ossenkoppele, Gj; Gedde Dahl, T; Hjorth Hansen, H; Jedrzejczak, W; Dmoszynska, A; Starzak Dwozdz, J; Holowiecki, J; Kyrcz Krzemieñ, S; Kuliczkowski, K; Zaritsky, A; Turkina, A; Pospelova, T; Goh, Yt; Koh, Lp; Demitrovicova, L; Mistrik, M; Ruff, P; Louw, V; Dreosti, Lm; Novitzky, N; Cohen, G; Cervantes, F; Cañizo, C; de Paz, R; del Castillo, S; Perez Encinas, M; Sanz Alonso, M; Marin, F; Pérez López, R; Hernandez Boluda, J; Echeveste Gutierrez, Ma; Odriozola, J; Herrera, P; Steegman, Jl; Conde, E; Lopez, P; Giraldo, P; Boque, C; Heredia, B; Font, Aj; Rodriguez, Rf; Rodriguez, Mj; Batlle, J; Stenke, L; Lehmann, S; Wadenvik, H; Simonsson, B; Markevärn, B; Själander, A; Richter, J; Bjoreman, M; Eriksson, Km; Chalandon, Y; Shih, Ly; Yao, M; Wang, Mc; Jootar, S; Bunworasate, U; Ulkü, B; Haznedar, R; Undar, B; Sahin, B; Marin, D; Smith, G; Byrne, J; Holyoake, T; Kalaycio, M; Akard, L; Heaney, M; Al Janadi, A; Goldberg, S; Powell, B; Harker, Wg; Shea, T; Gingrich, R; Glass, J; Paquette, R; Siegrist, C; Woodson, M; Fehrenbacher, L; Koh, H; Flinn, I; Arrowsmith, E; Ervin, T; Guerra, M; Wallach, H; Berry, W; Burke, J; Edenfield, W; Guzley, G; Davis, J; Richards, D; Schlossman, D; Kolibaba, K; Alemany, C; Savin, M; Robbins, G; Lopez, J; Goldman, Jm; Camm, J; Schiffer, Ca; Sargent, D. J.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - ELETTRONICO. - 362:24(2010), pp. 2251-2259.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM; Moiraghi B; Perez M; Greil R; Valent P; Bosly A; Martiat P; Noens L; André M; Verhoef G; Conchon M; Souza C; Nonino A; Hungria V; Zanichelli MA; Colturato V; Forrest D; Lipton JH; Savoie ML; Delage R; Lalancette M; Quintero G; Gomez M; Klamova H; Faber E; Bjerrum OW; Fredriksen H; Vestergaard H; Marcher C; Kamel H; Elzawam H; Porkka K; Remes K; Reiffers J; Guilhot F; Facon T; Tulliez M; Guerci Bresler AP; Nicolini FE; Charbonnier A; Rea D; Johnson Ansah A; Legros L; Harousseau JL; Rigal Huguet F; Escoffre M; Gardembas M; Guyotat D; Cahn JY; Gattermann N; Ottmann O; Niederwieser D; Stegelmann F; Schafhausen P; Brümmendorf T; Duyster J; Blumenstengel K; Scheid C; Kneba M; Kwong YL; Masszi T; Petrini M; Alimena G; Di Raimondo F; Rosti G; Rotoli B; PANE, FABRIZIO ;Pungolino E; Amadori S; Abruzzese E; Fioritoni G; Lauria F; Bosi A; Martelli M; Rambaldi A; Ferrara F; Nobile F; Gobbi M; Carella AM; Orlandi EM; Leoni P; Tiribelli M; Levis A; Imamura M; Takahashi N; Tsukamoto N; Chiba S; Nagai T; Okamoto S; Miura O; Kurokawa M; Ohnishi K; Toba K; Nakao S; Tomita A; Miyamura K; Hino M; Maeda Y; Kimura A; Kawaguchi T; Miyazaki Y; Nakaseko C; Jinnai I; Matsuda A; Matsumura I; Ishikawa J; Ohyashiki K; Okada M; Usuki K; Kobayashi Y; Ohishi K; Imai K; Miyawaki S; Kanda Y; Park SY; Kim HJ; Sohn SK; Lee KH; Jung CW; Ong TC; Gómez Almaguer D; Kassack J; Ossenkoppele GJ; Gedde Dahl T; Hjorth Hansen H; Jedrzejczak W; Dmoszynska A; Starzak Dwozdz J; Holowiecki J; Kyrcz Krzemieñ S; Kuliczkowski K; Zaritsky A; Turkina A; Pospelova T; Goh YT; Koh LP; Demitrovicova L; Mistrik M; Ruff P; Louw V; Dreosti LM; Novitzky N; Cohen G; Cervantes F; Cañizo C; de Paz R; del Castillo S; Perez Encinas M; Sanz Alonso M; Marin F; Pérez López R; Hernandez Boluda J; Echeveste Gutierrez MA; Odriozola J; Herrera P; Steegman JL; Conde E; Lopez P; Giraldo P; Boque C; Heredia B; Font AJ; Rodriguez RF; Rodriguez MJ; Batlle J; Stenke L; Lehmann S; Wadenvik H; Simonsson B; Markevärn B; Själander A; Richter J; Bjoreman M; Eriksson KM; Chalandon Y; Shih LY; Yao M; Wang MC; Jootar S; Bunworasate U; Ulkü B; Haznedar R; Undar B; Sahin B; Marin D; Smith G; Byrne J; Holyoake T; Kalaycio M; Akard L; Heaney M; Al Janadi A; Goldberg S; Powell B; Harker WG; Shea T; Gingrich R; Glass J; Paquette R; Siegrist C; Woodson M; Fehrenbacher L; Koh H; Flinn I; Arrowsmith E; Ervin T; Guerra M; Wallach H; Berry W; Burke J; Edenfield W; Guzley G; Davis J; Richards D; Schlossman D; Kolibaba K; Alemany C; Savin M; Robbins G; Lopez J; Goldman JM; Camm J; Schiffer CA; Sargent D.J.
2010
Citazione
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia / Saglio, G; Kim, Dw; Issaragrisil, S; le Coutre, P; Etienne, G; Lobo, C; Pasquini, R; Clark, Re; Hochhaus, A; Hughes, Tp; Gallagher, N; Hoenekopp, A; Dong, M; Haque, A; Larson, Ra; Kantarjian, Hm; Moiraghi, B; Perez, M; Greil, R; Valent, P; Bosly, A; Martiat, P; Noens, L; André, M; Verhoef, G; Conchon, M; Souza, C; Nonino, A; Hungria, V; Zanichelli, Ma; Colturato, V; Forrest, D; Lipton, Jh; Savoie, Ml; Delage, R; Lalancette, M; Quintero, G; Gomez, M; Klamova, H; Faber, E; Bjerrum, Ow; Fredriksen, H; Vestergaard, H; Marcher, C; Kamel, H; Elzawam, H; Porkka, K; Remes, K; Reiffers, J; Guilhot, F; Facon, T; Tulliez, M; Guerci Bresler, Ap; Nicolini, Fe; Charbonnier, A; Rea, D; Johnson Ansah, A; Legros, L; Harousseau, Jl; Rigal Huguet, F; Escoffre, M; Gardembas, M; Guyotat, D; Cahn, Jy; Gattermann, N; Ottmann, O; Niederwieser, D; Stegelmann, F; Schafhausen, P; Brümmendorf, T; Duyster, J; Blumenstengel, K; Scheid, C; Kneba, M; Kwong, Yl; Masszi, T; Petrini, M; Alimena, G; Di Raimondo, F; Rosti, G; Rotoli, B; Pane, Fabrizio; Pungolino, E; Amadori, S; Abruzzese, E; Fioritoni, G; Lauria, F; Bosi, A; Martelli, M; Rambaldi, A; Ferrara, F; Nobile, F; Gobbi, M; Carella, Am; Orlandi, Em; Leoni, P; Tiribelli, M; Levis, A; Imamura, M; Takahashi, N; Tsukamoto, N; Chiba, S; Nagai, T; Okamoto, S; Miura, O; Kurokawa, M; Ohnishi, K; Toba, K; Nakao, S; Tomita, A; Miyamura, K; Hino, M; Maeda, Y; Kimura, A; Kawaguchi, T; Miyazaki, Y; Nakaseko, C; Jinnai, I; Matsuda, A; Matsumura, I; Ishikawa, J; Ohyashiki, K; Okada, M; Usuki, K; Kobayashi, Y; Ohishi, K; Imai, K; Miyawaki, S; Kanda, Y; Park, Sy; Kim, Hj; Sohn, Sk; Lee, Kh; Jung, Cw; Ong, Tc; Gómez Almaguer, D; Kassack, J; Ossenkoppele, Gj; Gedde Dahl, T; Hjorth Hansen, H; Jedrzejczak, W; Dmoszynska, A; Starzak Dwozdz, J; Holowiecki, J; Kyrcz Krzemieñ, S; Kuliczkowski, K; Zaritsky, A; Turkina, A; Pospelova, T; Goh, Yt; Koh, Lp; Demitrovicova, L; Mistrik, M; Ruff, P; Louw, V; Dreosti, Lm; Novitzky, N; Cohen, G; Cervantes, F; Cañizo, C; de Paz, R; del Castillo, S; Perez Encinas, M; Sanz Alonso, M; Marin, F; Pérez López, R; Hernandez Boluda, J; Echeveste Gutierrez, Ma; Odriozola, J; Herrera, P; Steegman, Jl; Conde, E; Lopez, P; Giraldo, P; Boque, C; Heredia, B; Font, Aj; Rodriguez, Rf; Rodriguez, Mj; Batlle, J; Stenke, L; Lehmann, S; Wadenvik, H; Simonsson, B; Markevärn, B; Själander, A; Richter, J; Bjoreman, M; Eriksson, Km; Chalandon, Y; Shih, Ly; Yao, M; Wang, Mc; Jootar, S; Bunworasate, U; Ulkü, B; Haznedar, R; Undar, B; Sahin, B; Marin, D; Smith, G; Byrne, J; Holyoake, T; Kalaycio, M; Akard, L; Heaney, M; Al Janadi, A; Goldberg, S; Powell, B; Harker, Wg; Shea, T; Gingrich, R; Glass, J; Paquette, R; Siegrist, C; Woodson, M; Fehrenbacher, L; Koh, H; Flinn, I; Arrowsmith, E; Ervin, T; Guerra, M; Wallach, H; Berry, W; Burke, J; Edenfield, W; Guzley, G; Davis, J; Richards, D; Schlossman, D; Kolibaba, K; Alemany, C; Savin, M; Robbins, G; Lopez, J; Goldman, Jm; Camm, J; Schiffer, Ca; Sargent, D. J.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - ELETTRONICO. - 362:24(2010), pp. 2251-2259.
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Sei sicuro che questo prodotto debba essere cancellato?
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione.
